PVCT News 2.2600 Provectus Pharma (PVCT)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Provectus Pharma (PVCT) 2.2600 $PVCT

Provectus Biopharmaceuticals Signs Agreement with China's Tririver Capital
Business Wire - Mon Apr 14, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (OTCQB VCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that it has entered into an advisory agreement with China's Tririver Capital to help identify distribution and joint venture partners for the Company's novel oncology drug PV-10 in China, as well as other therapeutics that Provectus is developing.

Induction of Systemic Immunity Following Treatment of Tumors with PV-10 Reported by Moffitt Cancer Center Researchers at American Association for Cancer Research Annual Meeting
Business Wire - Mon Apr 07, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (OTCQB VCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that a poster presentation detailing significant decrease in melanoma cells in patients' injected tumors 7-14 days after intralesional PV-10 treatment that was accompanied by similar decrease in uninjected bystander tumors was presented April 6 by researchers from the Moffitt Cancer Center at the American Association for Cancer Research Annual Meeting in San Diego, CA. These clinical and pathologic changes were accompanied by increases in important immune cell populations detected in the patients' peripheral blood.

Provectus Biopharmaceuticals' PV-10 Data to Feature in Poster Presentation by Moffitt Cancer Center at the American Society of Clinical Oncology (ASCO) Annual Meeting
Business Wire - Wed Apr 02, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (OTCQB VCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that data on its investigational drug PV-10 will be featured in a presentation by investigators from Moffitt Cancer Center in a Poster Highlights Session of the American Society of Clinical Oncology (ASCO) Annual Meeting at McCormick Place, Chicago, IL, May 30-June 3, 2014. The time and date of the presentation are expected to become available on the ASCO website, http://am.asco.org, on April 21, 2014.

Provectus Biopharmaceuticals' PV-10 Data to Be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
Business Wire - Tue Apr 01, 5:30AM CDT
--McCormick Place in Chicago, IL, May 30-June 3, 2014

Provectus Biopharmaceuticals' PV-10 Data to Be Presented at the HemOnc Today Melanoma and Cutaneous Malignancies Conference
Business Wire - Tue Apr 01, 5:00AM CDT
Provectus Biopharmaceuticals, Inc. (OTCQB VCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that data on PV-10 for cutaneous melanoma will be included in a session at HemOnc Today - Melanoma and Cutaneous Malignancies Conference. HemOnc Today will be held this year at the Sheraton New York Times Square in New York City on Friday, April 11 and Saturday, April 12, 2014.

Provectus Biopharmaceuticals expects US FDA's Breakthrough Therapy Designation for PV-10 for melanoma within 60 days of receipt of application
M2 - Tue Mar 25, 6:14AM CDT
Biopharmaceutical company Provectus Biopharmaceuticals (Other OTC VCT) said on Monday that it has submitted an application for PV-10 for the treatment of melanoma under the US FDA's Breakthrough Therapy Designation (BTD).

Provectus Biopharmaceuticals Inc. Submits Application to FDA to Receive Breakthrough Therapy Designation for PV-10 for Treatment of Melanoma
Business Wire - Mon Mar 24, 5:05AM CDT
Provectus Biopharmaceuticals, Inc. (OTCQB VCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that it has applied to the FDA for Breakthrough Therapy Designation (BTD) for PV-10 for the treatment of melanoma. FDA guidelines state that the Agency will make a decision on the application within 60 days of receipt. The Agency's records for FY 2013 show that the Agency's Center for Drug Evaluation and Research (CDER) met that guideline 97% of the time.

Provectus names Dr Joseph M. Chalil to strategic advisory board
M2 - Thu Mar 20, 8:20AM CDT
Oncology company Provectus Biopharmaceuticals (Other OTC VCT) disclosed on Wednesday that Dr Joseph M. Chalil, MD, MBA, FACHE, has been elected to its strategic advisory board.

Provectus names Dr Joseph M. Chalil to Strategic Advisory Board
M2 - Wed Mar 19, 8:34AM CDT
Provectus Biopharmaceuticals, Inc. (OTC: PVCT), a development-stage oncology and dermatology biopharmaceutical company, today announced the appointment of Dr Joseph M. Chalil to its strategic advisory board.

Provectus Pharmaceuticals, Inc. Melanoma Version of PV-10 Completes Phase 2 and is Prepping for BTD
PR Newswire - Thu Mar 13, 11:04AM CDT
Provectus Pharmaceuticals, Inc. (OTC: PVCT) The melanoma version of the drug is the closest to market release. Phase 2 data was finalized in October 2012 and the drug is being prepped for Breakthrough Therapy Designation (BTD) Drug Submission with the FDA and is in the final steps for approval. Once submitted PVCT should receive a decision within 60 days of receipt of that request.

Biotech Breakthroughs Brings Powerful Cancer Testing and Drugs to Market
PR Newswire - Tue Feb 18, 6:00AM CST
New trial confirms MetaSite Breast test's ability to predict breast cancer metastasis. MetaSite Breast would allow doctors and patients to customize breast cancer treatment based on the cancer's probability of metastasizing.

Sanofi's CEO Admits Lackluster Drug Development Decade but Defends Its Pipeline: Sanofi (OTCQB: SNYNF), Royal Dutch Shell Plc (OTCQB: RYDAF), FUJIFILM Holdings Corp. (OTCPINK: FUJIY), Provectus Pharmaceuticals (OTC: PVCT)
ACCESSWIRE - Mon Feb 10, 10:12AM CST
The fierce competition coming from generic drug companies, the escalating costs of developing new drugs and the arduous process of getting them approved weighs heavily on Sanofi (OTCQB: SNYNF) and its competitors.

TrendingWallStreet.com Begins Trending PVCT, ORMP, KO, and MCIG
ACCESSWIRE - Mon Feb 03, 11:27PM CST
Whether it's a bull or bear market, TrendingWallStreet has you covered. Take a few minutes to register with us at http://www.trendingwallstreet.com/ to get exclusive access to our free stock reports.

Biotech Stock Mailbag: Cell Therapeutics and the Ariad Hostile React-o-Meter Meltdown
at The Street - Fri Jan 31, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Tranzbyte's Medical-Marijuana Dispensary Deal Falls Apart: Tranzbyte Corp. (OTCPINK: ERBB), Neutra Corp. (OTCQB: NTRR), Provectus Pharmaceuticals (OTC: PVCT)
ACCESSWIRE - Thu Jan 30, 8:47AM CST
Tranzbyte Corp. (OTCPINK: ERBB) was forced to take back the good news that it had struck a deal with a medical-marijuana dispensary to use the dispensary units it sells.

CORRECTION: Provectus's PV-10 path to initial approval in US now clear per FDA meeting minutes
M2 - Tue Jan 28, 9:11AM CST
Correction to headline: Provectus Biopharmaceuticals Inc (OTC VCT), a US-based developer of prescription drugs in oncology and dermatology, announced on Friday that it received the official minutes from a Type C meeting held with the US Food and Drug Administration (FDA) Division of Oncology Products 2, on 16 December 2013.

Federal Court Ruling Could Be Set Back for Royal Dutch Shell Stock: Royal Dutch Shell Plc (OTCQB: RYDAF), FUJIFILM Holdings Corp. (OTCPINK: FUJIY), Sanofi (OTCQB: SNYNF), Provectus Pharmaceuticals (OTC: PVCT)
ACCESSWIRE - Mon Jan 27, 2:01PM CST
Whether a recent federal court ruling will scrap Royal Dutch Shell Plc (OTCQB: RYDAF) Alaska drilling plans remains to be seen, but the uncertainty it creates could affect the oil company's share price.

Provectus announces clearance of initial approval for PV-10 in US
M2 - Mon Jan 27, 6:23AM CST
Provectus Biopharmaceuticals Inc (OTC VCT), a US-based developer of prescription drugs in oncology and dermatology, announced on Friday the receipt of the official minutes from the Type C meeting held with the US Food and Drug Administration (FDA) Division of Oncology Products 2, on 16 December 2013.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 167

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Engrain's Geospatial Innovation Pushes Property Mapping Forward

Updated Category News Views 86

Pushing the Boundaries of Property Mapping How far can you expand the boundaries of property mapping tech? Well, Engrain seems hell-bent on finding out by cranking their innovations up a notch. The Denver-based stalwart in interactive mapping is rolling out some mind-boggling enhancements that could redefine how the multifamily housing sector operates. This isn't just...

Continue Reading
LongueVue Capital: Betting Big on Sports & Entertainment

Updated Category News Views 78

LongueVue Capital's Bold Move You don’t always hear about private equity firms diving head-first into the sports and entertainment sector, but LongueVue Capital (LVC) is doing just that. This New Orleans-based firm is shifting its gears and setting sights on founder-owned ventures crucial to these industries. They’re asking the key question: Why focus on just the...

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 81

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 99

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
WHP Global's Japan Move: A Major Toy Market Play

Updated Category News Views 50

New Horizons for Toys"R"Us in Japan Well, folks, look who's back in the toy game with a vengeance! WHP Global is shaking hands with Pan Pacific International Holdings (PPIH) to breathe new life into Toys"R"Us across Japan. Now PPIH isn’t just any player. We're talking about Japan's fourth-largest retailer, helming giants like Don Quijote and aiming to crown itself as...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 16

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
Arbor Realty Trust Faces Securities Fraud Allegations

Updated Category News Views 5

Securities Lawsuit Against Arbor Realty Trust Looms Well, here we go again. Another day, another securities lawsuit hitting the headlines. This time it's Arbor Realty Trust (NYSE: ABR) getting caught in the crossfire, accused of pulling the wool over investors' eyes. Seems like 'truth in advertising' is just part of the PR playbook for some big shots. Understanding the...

Continue Reading
Tips for a Dementia-Friendly Thanksgiving Gathering

Updated Category News Views 55

Thanksgiving's supposed to bring families round the table, right? But toss a few knuckleheads together, add a pinch of dementia, and suddenly it's like throwing dice at a craps table. The American Speech-Language-Hearing Association (ASHA) reckons they've got tricks up their sleeve to keep the holiday from unraveling. The Thanksgiving Reality Check The hustle, bustle, and...

Continue Reading
BETR's Legal Tangle: A Deeper Dive into Investor Turmoil

Updated Category News Views 17

BETR's Shaky Ground: When Promises Fall Short In the rough-and-tumble world of finance, there's little room for empty promises. Better Home & Finance Holding Company (NASDAQ: BETR) might have to learn that the hard way. Investors who snagged shares between March 13 and August 6, 2026, are now clutching their heads as they watch their investments nosedive. When companies...

Continue Reading

Top 5 Most Recently Viewed Articles

Vizzy Hard Seltzer Unveils Exciting Cream Pop Variety Pack

Updated Category News Views 247

Vizzy Hard Seltzer Expands Flavor Options with New Variety Pack Vizzy Hard Seltzer is making waves by introducing its delightful Cream Pop Variety Pack, which marks a new chapter in its product line. This exciting pack is all set to enhance your sipping experience with flavors inspired by cherished childhood treats. Bringing together the well-loved Orange Cream Pop and...

Continue Reading
X-Bow Systems Expands DoD Partnership with New Funding Boost

Updated Category News Views 406

Significant Funding Boost for X-Bow Systems X-Bow Systems Inc. is making waves in the defense industry with its recent expansion of a crucial contract with the Department of Defense (DoD). This boost in funding follows a notable $64 million awarded in 2023 aimed at enhancing the production capacity of solid rocket motors. With this additional investment, X-Bow aims to...

Continue Reading
Digerati Technologies Mourns the Loss of Founding CEO Arthur Smith

Updated Category News Views 211

A Tribute to CEO Arthur L. Smith of Digerati Technologies Digerati Technologies, Inc. (OTC: DTGI), known for its dedicated approach to cloud services, recently lost its revered Founder and Chief Executive Officer, Arthur L. Smith. His passing has left a profound impact on the company, its employees, and the broader business community. Honoring a Visionary Leader Arthur L....

Continue Reading
Investors Encouraged to Engage in Transocean Ltd. Lawsuit

Updated Category News Views 142

Opportunity for Transocean Ltd. Investors Recent developments have opened a new chapter for investors of Transocean Ltd. (NYSE: RIG). Those who purchased securities between October 31, 2023, and September 2, 2024, referred to as the "Class Period," are now being called to action. This is a moment not just for individual investors, but a collective initiative to ensure...

Continue Reading
Blue Owl Capital Sets New Milestones with OWL Stock Growth

Updated Category News Views 144

Blue Owl Capital's Remarkable Stock Surge In a noteworthy display of market confidence, OWL stock has reached an impressive price level of $23.7, marking an all-time high. This significant milestone highlights the company's strong performance and the optimistic outlook investors have regarding its potential for growth. Over the last year, the company has experienced an...

Continue Reading